CRISPR Therapeutics AG Annual Net Cash Provided by (Used in) Operating Activities in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
CRISPR Therapeutics AG quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from 2016 to 2023.
  • CRISPR Therapeutics AG Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2024 was $110M, a 1147% increase year-over-year.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$260M, a 47.5% increase from 2022.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$496M, a 192% decline from 2021.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Operating Activities for 2021 was $539M.
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$260M +$235M +47.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 -$496M -$1.03B -192% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 $539M +$777M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$238M -$295M -521% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $56.7M +$153M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$96.2M -$26.1M -37.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$70.1M -$17.2M -32.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 -$52.9M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.